Processa Pharmaceuticals Inc. Common Stock (PCSA)
Stock · NASDAQ · Health Care
$1.68as of 10/16/2026
Price chart
Active signals
PCSA Signal Track Record
How signals performed across all stocks →What PCSA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 21 | -4.4% | 14% | October 1, 2026 |
| Volume Spike | 19 | -7.0% | 26% | September 8, 2026 |
| Bollinger Band Breakout | 14 | -15.3% | 29% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -18.9% | 0% | December 8, 2025 |
| Any 20-session window (baseline) | -11.2% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pip…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12
Fundamentals
- 1-day range
- $1.63$1.74
- Market cap
- $7.65M
- P/E (trailing)
- 3.31
- P/E (forward)
- -0.44
- EPS (trailing)
- $-5.77
- Dividend yield
- —
- Beta
- 1.33
- Avg. volume
- 274.6K
- Dividend pay date
- December 23, 2019
How Processa Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2016 annual results
Source: 10-K filed Sep 25, 2017 · via SEC EDGAR / Finnhub
Processa Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Processa Pharmaceuticals Files Prospectus For Offering 306.574M Common Shares On Behalf Of Selling Shareholdersbenzinga · 10/9/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/9/2026
- Processa Pharmaceuticals Files Prospectus For Offering 306.574M Common Shares On Behalf Of Selling ShareholdersBenzinga · 10/9/2026
Insider Activity
Insider Actions →- George K. Ng · August 8, 2026 · Option Exercise1.6K
- Sheila Gujrathi · July 28, 2026 · Grant12.3K
- Sheila Gujrathi · July 28, 2026 · Grant70.8K
- Geraldine Pannu · July 26, 2026 · Grant33.5K
- George K. Ng · July 26, 2026 · Grant9.4K
- James R. Neal · July 26, 2026 · Grant62.2K
- Patrick Lin · July 26, 2026 · Grant8.4K
- Wendy Guy · July 26, 2026 · Grant9.4K
- Khoso Baluch · July 26, 2026 · Grant33.5K
- Justin W. Yorke · July 26, 2026 · Grant33.5K
- Russell Skibsted · July 26, 2026 · Grant11.9K
- George K. Ng · July 1, 2026 · Buy3.1K @ $1.93
- David Young · June 30, 2026 · Buy2.5K @ $1.93
- Russell Skibsted · June 30, 2026 · Buy3.3K @ $1.93
- Wendy Guy · June 30, 2026 · Buy2.4K @ $1.93
Institutional Ownership
March 31, 2026
- Total shares held
- 166.8K
- Total value held
- $421.1K
- Institutional holders
- 9
- Unknown70.7K
- Unknown55.0K
- Unknown24.9K
- Unknown12.7K
- Unknown2.5K
- Unknown918
- Unknown14
- Unknown7
- Unknown6
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.